{"id":"NCT05096221","sponsor":"Sarepta Therapeutics, Inc.","briefTitle":"A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)","officialTitle":"A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-10-27","primaryCompletion":"2023-10-04","completion":"2024-10-25","firstPosted":"2021-10-27","resultsPosted":"2024-12-10","lastUpdate":"2025-07-08"},"enrollment":126,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Duchenne Muscular Dystrophy"],"interventions":[{"type":"GENETIC","name":"delandistrogene moxeparvovec","otherNames":["SRP-9001","delandistrogene moxeparvovec-rokl","ELEVIDYS"]},{"type":"GENETIC","name":"placebo","otherNames":[]}],"arms":[{"label":"Delandistrogene Moxeparvovec followed by Placebo","type":"EXPERIMENTAL"},{"label":"Placebo followed by Delandistrogene Moxeparvovec","type":"PLACEBO_COMPARATOR"}],"summary":"The study will evaluate the safety and efficacy of gene transfer therapy in boys with DMD. It is a randomized, double-blind, placebo-controlled study. The participants who are randomized to the placebo arm will have an opportunity for treatment with gene transfer therapy at the beginning of the second year.","primaryOutcome":{"measure":"Part 1: Change From Baseline in North Star Ambulatory Assessment (NSAA) Total Score at Week 52","timeFrame":"Baseline, Week 52 (Part 1)","effectByArm":[{"arm":"Delandistrogene Moxeparvovec Followed by Placebo","deltaMin":2.57,"sd":0.39},{"arm":"Placebo Followed by Delandistrogene Moxeparvovec","deltaMin":1.92,"sd":0.39}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2441"}]},"eligibility":{"minAge":"4 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":3},"locations":{"siteCount":42,"countries":["United States","Belgium","Germany","Hong Kong","Italy","Japan","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["39385046","40354061","39589719"],"seeAlso":["https://www.sarepta.com/sites/sarepta-corporate/files/2025-06/SRP-9001-301_English_PLSS.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":63},"commonTop":["Vomiting","Cough","Nausea","Upper respiratory tract infection","Pyrexia"]}}